LX
LXRX.US Lexicon Pharmaceuticals Inc
- Market cap
- USD 797M
- P/E
- -
- P/B
- 4.86x
- ROE
- -38.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is LXRX.US undervalued?
Graham numberThe Graham number of Lexicon Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Lexicon Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Lexicon Pharmaceuticals Inc yet.
Lexicon Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Lexicon Pharmaceuticals Inc
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiov…
Full company profileLexicon Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Lexicon Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 83.3M | 90.3M | 63.2M | 322M | 24.0M | 298K | 139K | 1.20M | 31.1M | 49.8M | 44.1M |
| Gross Profit | -80.6M | 88.4M | 60.7M | 319M | 22.1M | -54.7M | -52.4M | -57.8M | 30.5M | 49.5M | 43.8M |
| Operating Income | -137M | -137M | -103M | 141M | -47.8M | -87.1M | -101M | -172M | -197M | -48.9M | -56.0M |
| EBITDA | -126M | -125M | -96.1M | 148M | -41.1M | -86.7M | -100M | -170M | -184M | -41.4M | -57.1M |
| Net Income | -141M | -129M | -121M | 130M | -58.6M | -87.8M | -102M | -177M | -200M | -50.3M | -62.4M |
| EPS | -1.36 | -1.23 | -1.14 | 1.11 | -0.53 | -0.60 | -0.62 | -0.80 | -0.63 | -0.14 | -0.14 |
| Balance Sheet | |||||||||||
| Total Assets | 476M | 437M | 284M | 418M | 204M | 137M | 194M | 229M | 298M | 185M | 242M |
| Total Liabilities | 318M | 384M | 311M | 301M | 47.4M | 23.3M | 77.2M | 136M | 152M | 77.4M | 78.2M |
| Shareholders' Equity | 157M | 52.1M | -1.47B | 117M | 156M | 114M | 117M | 93.1M | 146M | 108M | 164M |
| Cash & Short-term Investments | 347M | 311M | 160M | 272M | 152M | 86.7M | 138M | 170M | 238M | 96.2M | 183M |
| Total Debt | 101M | 246M | 245M | 247M | 12.8M | 2.28M | 55.3M | 106M | 108M | 62.2M | 59.5M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -176M | -185M | -149M | 114M | -143M | -87.0M | -88.9M | -162M | -179M | -67.9M | -62.3M |
| Capital Expenditure | 231K | 228K | 95.0K | 70.0K | 87.0K | 1.22M | 1.33M | 470K | 1.03M | 0.00 | 0.00 |
| Free Cash Flow | -176M | -186M | -149M | 114M | -143M | -88.2M | -90.2M | -162M | -180M | -67.9M | -62.3M |
| Ratios | |||||||||||
| ROE | -89.9% | -247.7% | - | 111.1% | -37.5% | -77.3% | -87.0% | -190.2% | -137.3% | -46.8% | -38.1% |
| ROA | -29.7% | -29.6% | -42.4% | 31.2% | -28.7% | -64.1% | -52.5% | -77.2% | -67.2% | -27.2% | -25.8% |
| Net Profit Margin | -169.7% | -142.9% | -190.7% | 40.4% | -244.1% | -29,449.0% | -73,341.0% | -14,710.9% | -644.8% | -101.1% | -141.7% |
| Debt to Equity | 0.64x | 4.72x | - | 2.11x | 0.08x | 0.02x | 0.47x | 1.14x | 0.74x | 0.58x | 0.36x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Lexicon Pharmaceuticals Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | USD 99.9M | 0.45 | - |
| 2022 | - | - | - |
| 2021 | USD 11.7M | 0.08 | - |
| 2020 | USD 217M | 1.95 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:7 on May 21, 2015.
Who owns Lexicon Pharmaceuticals Inc
- Insiders 1.53%
- Institutions 87.29%
- Public & others 11.18%
- Shares outstanding 445M
- Free float 219M
Top funds holding LXRX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Growth Company Fund | 20.7M | 4.64% | +8.46% | Aug 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 7.08M | 1.59% | 0.00% | Sep 2026 |
| Fidelity Growth Company K6 | 6.06M | 1.36% | +8.29% | Aug 2026 |
| iShares Russell 2000 ETF | 5.75M | 1.29% | 0.00% | Oct 2026 |
| Fidelity Select Biotechnology | 5.71M | 1.28% | +40.72% | Aug 2026 |
| Fidelity Series Growth Company | 5.06M | 1.14% | +10.92% | Aug 2026 |
| Fidelity Small Cap Index | 2.72M | 0.61% | 0.00% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 2.14M | 0.48% | -0.38% | Oct 2026 |
| State Street® SPDR® S&P® PhrmctlsETF | 2.02M | 0.45% | +2.88% | Oct 2026 |
| Vanguard Russell 2000 ETF | 1.32M | 0.30% | -7.91% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 1.12M | 0.25% | +0.24% | Oct 2026 |
| Fidelity Extended Market Index | 1.02M | 0.23% | -8.15% | Sep 2026 |
| iShares Micro-Cap ETF | 689K | 0.15% | 0.00% | Oct 2026 |
| Vanguard US Momentum Factor ETF | 658K | 0.15% | 0.00% | Sep 2026 |
| Vanguard Health Care ETF | 646K | 0.15% | +0.11% | Sep 2026 |
| Schwab Small Cap Index | 552K | 0.12% | -8.69% | Sep 2026 |
| Fidelity Total Market Index | 425K | 0.10% | -0.05% | Sep 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 409K | 0.09% | -12.01% | Sep 2026 |
| Stt Strt SPDR® Russell2000 US SmCapETF | 407K | 0.09% | -5.91% | Oct 2026 |
| Fidelity Series Total Market Index | 352K | 0.08% | 0.00% | Sep 2026 |
Top institutions holding LXRX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Artal Group S A | 175M | 39.36% | +13.20% | Jun 2026 |
| FMR Inc | 51.8M | 11.64% | +14.93% | Jun 2026 |
| Siren, L.L.C. | 44.3M | 9.96% | 0.00% | Jun 2026 |
| Sessa Capital, L.P | 19.0M | 4.26% | +5.85% | Jun 2026 |
| BlackRock Inc | 17.3M | 3.90% | +422.20% | Jun 2026 |
| Vanguard Capital Management, LLC | 9.90M | 2.23% | +4.01% | Jun 2026 |
| Point72 Asset Management, L.P. | 8.25M | 1.85% | +5.59% | Jun 2026 |
| Geode Capital Management, LLC | 6.24M | 1.40% | +97.04% | Jun 2026 |
| State Street Corp | 4.92M | 1.11% | +410.12% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 2.36M | 0.53% | +331.35% | Jun 2026 |
| Northern Trust Corp | 1.97M | 0.44% | +297.97% | Jun 2026 |
| Charles Schwab Investment Management Inc | 1.96M | 0.44% | +49.22% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 1.63M | 0.37% | +22.69% | Jun 2026 |
| Citadel Advisors Llc | 1.60M | 0.36% | +46.24% | Jun 2026 |
| Ishara Investments LP | 1.27M | 0.29% | +40.91% | Jun 2026 |
| Millennium Management LLC | 1.13M | 0.25% | -77.06% | Jun 2026 |
| Mackenzie Investments | 963K | 0.22% | +24.68% | Jun 2026 |
| ADAR1 Capital Management LLC | 750K | 0.17% | 0.00% | Jun 2026 |
| Susquehanna International Group, LLP | 697K | 0.16% | -67.15% | Jun 2026 |
| UBS Group AG | 685K | 0.15% | -72.43% | Jun 2026 |
Lexicon Pharmaceuticals Inc company profile
- Company name
- Lexicon Pharmaceuticals Inc
- Ticker
- LXRX.US
- Exchange
- USA Stocks
- Listed since
- Apr 7, 2000
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 81
- Fiscal year end
- December
- Address
- 2445 Technology Forest Boulevard, The Woodlands, TX, United States, 77381
- Phone
- 281 863 3000
- Website
- lexpharma.com
About Lexicon Pharmaceuticals Inc
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Lexicon Pharmaceuticals Inc management
9- Dr. Michael S. Exton Ph.D.CEO & Director · born 1970
- Mr. Scott M. CoianteSenior VP & CFO · born 1967
- Mr. Brian T. CrumSenior VP, General Counsel & Secretary · born 1973
- Ms. Wendy E. McDermottSenior Vice President of Human Resources · born 1971
- Dr. Craig B. Granowitz M.D., Ph.D.Senior VP & Chief Medical Officer · born 1965
- Ms. Kristen L. AlexanderVice President of Finance & Accounting · born 1968
- Ms. Lisa M. DeFrancescoSenior Vice President of Investor Relations & Corporate Communications · born 1980
- Dr. Suma Gopinathan M.S., Ph.D.Senior Vice President of Discovery · born 1973
- Ms. Rachel Yap MartensSenior VP & Chief Commercial Officer · born 1984